Abstract
We investigated the uptake of nirsevimab for infants and the bivalent respiratory syncytial virus prefusion F (RSVPreF) vaccine for pregnant persons as measures for RSV prevention during an infant's birth hospitalization in a military treatment facility. We found >85% uptake between October 2023 to February 2024. These data may aid health systems plan for future RSV seasons.
| Original language | English |
|---|---|
| Pages (from-to) | 114144 |
| Journal | Journal of Pediatrics |
| Volume | 273 |
| DOIs | |
| State | Published - Oct 2024 |
| Externally published | Yes |
Keywords
- Humans
- Infant, Newborn
- Respiratory Syncytial Virus Infections/prevention & control
- Female
- Pregnancy
- Respiratory Syncytial Virus Vaccines
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antiviral Agents/therapeutic use
- Military Personnel
- Male
- Hospitalization/statistics & numerical data